Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
βIV-Spectrin/STAT3 complex regulates fibroblast phenotype, fibrosis, and cardiac function
Nehal J. Patel, Drew M. Nassal, Amara D. Greer-Short, Sathya D. Unudurthi, Benjamin W. Scandling, Daniel Gratz, Xianyao Xu, Anuradha Kalyanasundaram, Vadim V. Fedorov, Federica Accornero, Peter J. Mohler, Keith J. Gooch, Thomas J. Hund
Nehal J. Patel, Drew M. Nassal, Amara D. Greer-Short, Sathya D. Unudurthi, Benjamin W. Scandling, Daniel Gratz, Xianyao Xu, Anuradha Kalyanasundaram, Vadim V. Fedorov, Federica Accornero, Peter J. Mohler, Keith J. Gooch, Thomas J. Hund
View: Text | PDF
Research Article Cardiology Cell biology

βIV-Spectrin/STAT3 complex regulates fibroblast phenotype, fibrosis, and cardiac function

  • Text
  • PDF
Abstract

Increased fibrosis is a characteristic remodeling response to biomechanical and neurohumoral stress and a determinant of cardiac mechanical and electrical dysfunction in disease. Stress-induced activation of cardiac fibroblasts (CFs) is a critical step in the fibrotic response, although the precise sequence of events underlying activation of these critical cells in vivo remain unclear. Here, we tested the hypothesis that a βIV-spectrin/STAT3 complex is essential for maintenance of a quiescent phenotype (basal nonactivated state) in CFs. We reported increased fibrosis, decreased cardiac function, and electrical impulse conduction defects in genetic and acquired mouse models of βIV-spectrin deficiency. Loss of βIV-spectrin function promoted STAT3 nuclear accumulation and transcriptional activity, and it altered gene expression and CF activation. Furthermore, we demonstrate that a quiescent phenotype may be restored in βIV-spectrin–deficient fibroblasts by expressing a βIV-spectrin fragment including the STAT3-binding domain or through pharmacological STAT3 inhibition. We found that in vivo STAT3 inhibition abrogates fibrosis and cardiac dysfunction in the setting of global βIV-spectrin deficiency. Finally, we demonstrate that fibroblast-specific deletion of βIV-spectrin is sufficient to induce fibrosis and decreased cardiac function. We propose that the βIV-spectrin/STAT3 complex is a determinant of fibroblast phenotype and fibrosis, with implications for remodeling response in cardiovascular disease (CVD).

Authors

Nehal J. Patel, Drew M. Nassal, Amara D. Greer-Short, Sathya D. Unudurthi, Benjamin W. Scandling, Daniel Gratz, Xianyao Xu, Anuradha Kalyanasundaram, Vadim V. Fedorov, Federica Accornero, Peter J. Mohler, Keith J. Gooch, Thomas J. Hund

×

Figure 7

Fibroblast-specific deletion of βIV-spectrin leads to altered gene expression and STAT3 dysregulation in cardiac fibroblasts (CFs) together with decreased cardiac function and fibrosis.

Options: View larger image (or click on image) Download as PowerPoint
Fibroblast-specific deletion of βIV-spectrin leads to altered gene expre...
(A) The βIV-spectrin floxed mouse was cross-bred with the periostinMerCreMer mouse to generate an inducible fibroblast-specific βIV-spectrin KO mouse (βIV-ifKO). Two-week treatment of animals with angiotensin II (2.16 mg/kg i.p. injection daily) together with tamoxifen (75 mg/kg i.p. injection daily) (+Tam/Ang II) was used to ensure robust activity of periostinMerCreMer (periostin highly expressed in activated fibroblasts) and effective βIV-spectrin KO in cardiac fibroblasts (22). (B) Expression of select fibrotic genes (relative to Rpl7) determined by qPCR in CFs isolated from control (βIV-spectrin floxed, Cre-) and βIV-ifKO following 2 weeks of tamoxifen/angiotensin II treatment (+tam/AngII). Data presented as mean ± SEM; n = 3 for control and n = 4 for βIV-ifKO where N is the number of independent preparations; *P < 0.05 by 2-tailed t test. (C) Representative confocal microscopy images (original magnification, ×10) of permeabilized adult control and βIV-ifKO CFs immunostained for βIV-spectrin (red), STAT3 (green), phalloidin (gray in merged image), and DAPI (blue in merged image). White asterisk in merged images indicates region of zoom shown in far right panel. Scale bar: 20 mm. (D and E) Summary data (mean ± SEM) of βIV-spectrin immunoreactive signal (normalized to DAPI) and STAT3 nuclear localization in control and βIV-ifKO CFs. n = 4 per group where N is the number of independent preparations (5 fields analyzed per preparation for βIV-spectrin and 5 cells analyzed per preparation for STAT3 nuclear localization); *P < 0.05 by 2-tailed t test. (F) Masson’s trichrome–stained ventricular heart sections (collagen labeled blue, original magnification, ×20). Scale bars: 200 μm. (G) Summary data (mean ± SEM) showing fibrosis as percentage of tissue area. n = 3 different hearts for each group (4 longitudinal sections of entire ventricles analyzed per animal); *P < 0.05 by 1-way ANOVA and Holm-Sidak post hoc pairwise comparison. (H) Representative echocardiograms and (I) summary data (mean ± SEM) for ejection fraction from control and βIV-ifKO animals at baseline and following 2 weeks of tamoxifen/angiotensin II treatment. n = 7 for control baseline; n = 6 for control+tam/AngII; n = 10 for βIV-ifKO baseline; n = 8 for βIV-ifKO+tam/AngII where N represents the number of animals; *P < 0.05 by 1-way ANOVA and Holm-Sidak post hoc pairwise comparison.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts